Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.36 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 3/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 2/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | CFD | P00746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14411409 | 1.00 | PDE10A (0.36) | PDE10AFSCN1ALKCNR2DRD2 | |
| SCHEMBL5454207 | 1.00 | PDE10A (0.36) | PDE10AFSCN1ALKCNR2DRD2 | |
| SCHEMBL5448872 | 0.94 | PPARG (0.37) | PDE10AFSCN1CNR2DRD2ADRA1D | |
| SCHEMBL14411406 | 0.94 | PPARG (0.37) | PDE10AFSCN1CNR2DRD2ADRA1D | |
| SCHEMBL5448868 | 0.94 | PPARG (0.37) | PDE10AFSCN1CNR2DRD2ADRA1D | |
| SCHEMBL5454298 | 0.93 | FSCN1 (0.39) | PDE10AFSCN1ALKCNR2 | |
| SCHEMBL14411412 | 0.93 | FSCN1 (0.39) | PDE10AFSCN1ALKCNR2 | |
| SCHEMBL5454301 | 0.93 | FSCN1 (0.39) | PDE10AFSCN1ALKCNR2 | |
| SCHEMBL5460650 | 0.93 | CNR2 (0.41) | PDE10ACNR2CFD | |
| SCHEMBL14411439 | 0.93 | CNR2 (0.41) | PDE10ACNR2CFD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | PDE10A 514/4885FSCN1 4090/4885ALK 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.